Trials / Recruiting
RecruitingNCT07230730
A Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 900 (estimated)
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the efficacy, and safety of SHR-1918 in reducing serum low-density lipoprotein cholesterol (LDL-C) and total triglycerides (TG) in patients with hyperlipidemia compared with placebo, and also includes To evaluate the effectiveness of SHR-1918 in reducing other lipid indicators in patients with mixed hyperlipidemia and to assess the safety of SHR-1918 in patients with mixed hyperlipidemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1918 | SHR-1918 |
| DRUG | SHR-1918 placebo | SHR-1918 placebo |
Timeline
- Start date
- 2026-01-13
- Primary completion
- 2027-10-01
- Completion
- 2027-10-01
- First posted
- 2025-11-17
- Last updated
- 2026-02-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07230730. Inclusion in this directory is not an endorsement.